Navigation Links
Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium

SAN JOSE, Calif., Nov. 14 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, announced that interim results from two multi-center studies using the VNUS ClosureFAST catheter were presented today at the 34th Annual VEITH Symposium in New York. The VNUS ClosureFAST(TM) catheter is an endovenous radiofrequency (RF) ablation catheter designed to heat and close diseased saphenous veins - the underlying cause of varicose veins.

In a presentation titled "ClosureFAST Is Better Than First Generation Radiofrequency Ablation: A Quantum Leap Forward", Alan Dietzek, MD., Chief of Vascular Surgery and Linda and Stephen R Cohen Chair in Vascular Surgery at Danbury Hospital in Danbury, Connecticut, presented one-year follow-up results of ClosureFAST patients from a multi-center prospective study including 13 centers in the US and Europe. Among 324 patients (395 limbs) in the study, 142 limbs had one-year followup data, with a vein occlusion rate of 96.2% at one year using Kaplan-Meier analysis.

"VNUS ClosureFAST is a major step forward in the management of venous disease," said Dr. Dietzek. "Results so far have exceeded expectations, especially the excellent treatment efficacy combined with very mild postoperative patient recovery. Furthermore, with ClosureFAST it is now possible to perform endovenous ablation of the saphenous vein as fast or faster than with any other device or mode of treatment available."

Jose I. Almeida, MD., FACS, founder of the Miami Vein Center in Miami, Florida and a recognized expert in varicose vein treatment, presented the interim results of the Recovery trial, a multi-center randomized trial comparing the ClosureFAST treatment to endovenous laser. Patients undergoing laser treatment were 33% more likely to experience pain and 50% more likely to require postoperative pain medication than patients who received the ClosureFast treatment.

"The ClosureFAST device is clearly emerging as the preferred treatment for venous reflux, in part because of reduced patient discomfort after treatment," said Dr. Almeida. "While procedure time and short-term efficacy are comparable between ClosureFAST and laser, we're definitely seeing a superior patient recovery profile with ClosureFAST."

"We are pleased to see the positive interim study results on our ClosureFAST catheter, especially the favorable patient recovery profile compared to laser treatment and the better-than-anticipated one-year efficacy rate," said Brian E. Farley, President and CEO of VNUS. "We believe the final results will support our belief that ClosureFAST is the best choice for the treatment of venous reflux disease for the millions of varicose vein sufferers around the world."


Now in its fourth decade, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The five-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. VEITHsymposium is sponsored by The Cleveland Clinic, Cleveland, OH.


Founded in 1995 and headquartered in San Jose, California, VNUS Medical Technologies (Nasdaq: VNUS) is a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that causes the varicose veins afflicting 25 million Americans. The pioneering company in the field, VNUS now offers the ClosureFAST system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to close diseased veins through the application of temperature-controlled RF energy. VNUS devices have been used in more than 250,000 procedures worldwide. For more information, please visit

SOURCE VNUS Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
5. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
6. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
(Date:11/24/2015)... DELHI , November 25, 2015 ... invoked due to repeated failure of IVF cycles. After ... Bhatia was totally dejected and had lost all hopes that she would be ... first Indian miracle child conceived after failure of over ... to abroad (UK) before they decided to take one last attempt ...
(Date:11/24/2015)...  In the pharmaceutical industry, companies want to rapidly ... uncover new insights, tactics and strategies that will improve ... --> However, organizations often find it is difficult ... that all rules and regulations are met to ensure ... to efficiently launching market research projects is the conflicting ...
(Date:11/24/2015)... , November 24, 2015 --> ... report "Spine Biologics Market by Product Type (Bone Graft, Bine ... Discectomy and Fusion, Posterior Lumbar Interbody Fusion), End User, and ... global market was valued at $1.90 Billion in 2014 and ... CAGR of 4.4% during the forecast period of 2015 to ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse located in ... staff members at their recovery center. The videos highlight some of the various aspects ... things that make their recovery program so unique. , “Making the decision to seek ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cold Shoulder , LLC launched their Pro Vest, the latest ... hit their goal of $20,000 in under 10 hours. , The campaign, ... PRO Weight Loss Vest to the market. , The PRO Vest provides consumers with a ...
(Date:11/24/2015)... ... ... Dr. Rodney E. Willey , has answered a new calling – to relieve snoring ... treatment for snoring and sleep apnea through oral appliance therapy. He is ... in the US, one of four in the Illinois area. , Dr. Willey’s ...
(Date:11/24/2015)... ... ... Bibliomotion is thrilled to announce the launch of UNCONVENTIONAL ... Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health System (November ... of patients and their families, shaped my desire to improve the system of care. ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... products, announces Innovative Blending, a household invention that revolutionizes the vending machine industry ... Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):